

JOHN B. CLEMMONS, JR., MD

PRIVATE PRACTICE GASTROENTEROLOGY BOARD CERTIFIED: INTERNAL
MEDICINE.

Gastroenterology
September 1, 1981 to present
Park Plaza Professional Building 1213 Herman
Drive, Suite 420 Houston, Texas 77004
Tel (713) 528-6562
Fax (713) 528-1045
drjbe3030@sbcglobalnet

EDUCATION:

September 1967- May 1971	Williams College Williamstown, MA Bachelor of Science
Williamstown, Mass. Bachelor of Scien	
June 1971- May 1975	Howard University College of Medicine Washington, D.C. Medical Degree
June 1975- June 1976	Watson Fellow
July 1976- June 1977	Residency, Internal Medicine Emory University School of Medicine Atlanta, GA
July 1979- June 1981	Fellowship, Gastroenterology Emory University School of Medicine Atlanta, GA

POSITION/COMMITTEES/AFFILIATIONS:

1987- 1992	Chief of Gastroenterology Park Plaza Hospital
------------	--

1989- 1991	President, Houston Medical Forum
1989- 1997	Program Coordinator, Flexible Sigmoidoscopy for the Primary Care Physician Park Plaza Hospital
1996- 1998	Executive Committee, Park Plaza Hospital
1998- 2002	Chair Encloscopy Committee, Park Plaza Hospital
2011- Present	Therapeutic Concepts, PA SubInvestigator for Clinical Trials 4900 Fannin Street Houston, Texas 77004
2011 - Present	Cure C Consortium Sub Investigator 4900 Fannin St. Houston, TX 77004

RESEARCH EXPERIENCE

1220.7: A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-a and ribavirin in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN/RBV treatment

1220.47: A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 24 weeks and BI 201335 240 mg for 12 weeks in combination with pegylated interferon-a and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection

1220.48: A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-a (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN/RBV treatment

TMC435-TiDP16-C212: A Phase III open-label study to evaluate the safety, tolerability and efficacy of TMC435 plus Pegintedeton PegIFNa-2a. (Pegasys®) and ribavirin (Copegus®) triple therapy in chronic hepatitis C genotype-1 infected subjects who are co-infected with human immunodeficiency virus type 1 (HIV-1).

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects with Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

